Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 14;24(1):316.
doi: 10.1186/s12879-024-09156-9.

HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon

Guy Francis Nzengui-Nzengui  1 , Gaël Mourembou  1 , Hervé M'boyis-Kamdem  1 , Ayawa Claudine Kombila-Koumavor  1 , Angélique Ndjoyi-Mbiguino  2
Affiliations

HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon

Guy Francis Nzengui-Nzengui et al. BMC Infect Dis. .

Abstract

Introduction: In 2022, the WHO reported that 29.8 million people around the world were living with HIV (PLHIV) and receiving antiretroviral treatment (ART), including 25‌ 375 people in Gabon (54% of all those living with HIV in the country). The literature reports a frequency of therapeutic failure with first-line antiretrovirals (ARVs) of between 20% and 82%. Unfortunately, data relating to the failure of second-line ARVs are scarce in Gabon. This study aims to determine the profiles of HIV drug resistance mutations related to protease inhibitors in Gabon.

Methodology: Plasma from 84 PLHIV receiving ARVs was collected from 2019 to 2021, followed by RNA extraction, amplification, and sequencing of the protease gene. ARV resistance profiles were generated using the Stanford interpretation algorithm version 8.9-1 ( https://hivdb.stanford.edu ) and statistical analyses were performed using EpiInfo software version 7.2.1.0 (CDC, USA).

Results: Of 84 HIV plasma samples collected from 45 men and 39 women, 342 mutations were detected. Of these, 43.3% (148/342) were associated with nucleoside reverse transcriptase inhibitors (NRTIs), 30.4% (104/342) with non-nucleoside reverse transcriptase inhibitors (NNRTIs), and 26.3% (90/342) with protease inhibitors (PIs). Most NRTI mutations were associated with thymidine analogues (TAMs) (50.7%; 75/148), including T215F/V (14.9%; 22/148), D67DN/E/G/N/T (10.1%; 15/148), M41L (9.5%; 14/148), and K70E/KN/S/R (9.5%; 14/148). Resistance mutations related to non-TAM NRTIs (33.1%; 49/148) were M184V (29.1%; 43/148), and L74I/V (8.1%; 12/148). NNRTI mutations were predominantly K103N/S (32.7%; 34/104), V108I (10.6%; 11/104), A98G (10.6%; 11/104), and P225H (9.6%; 10/104). Minor mutations associated with PIs (60.0%; 54/90) were predominantly K20I (15.6%; 14/90) and L10F/I/V (14.5%; 13/90). The major mutations associated with PIs (40.0%; 36/90) were M41L (12.2%; 11/90), I84V (6.7%; 06/90), and V82A (6.7%; 06/90). The four most prescribed therapeutic regimens were TDF + 3TC + LPV/r (20.3%; 17/84), ABC + DDI + LPV/r (17.9%; 15/84), TDF + FTC + LPV/r (11.9%; 10/84), and ABC + 3TC + LPV/r (11.9%; 10/84).

Conclusion: This study revealed that HIV drug resistance mutations are common in Gabon. The major mutations associated with PIs were M41L, I84V, and V82A. There is a need for access to new NRTIs, NNRTIs, and PIs for a better therapeutic management of PLHIV in Gabon.

Keywords: Antiretroviral; Gabon; HIV; Protease; Resistance mutations.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization. WHO-The top 10 causes of death. WHO. int. 2018. 9 December 2020. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 23 November 2023.
    1. Sheet Fact. Global HIV statistics people living with HIV people living with HIV accessing antiretroviral therapy New HIV infections AIDS- related deaths Key Populations.2023. 31 August 2023. https://www.unaids.org/en/resources/fact-sheet. Accessed 22 November 2023.
    1. Plan A, Resistance HIVD. November. Global Action Plan on HIV Drug Resistance 2017–2021, 2021. 1 july 2017. https://www.who.int/publications/i/item/978-92-4-151284-8. Accessed 22 2023.
    1. Weber IT, Wang Y, Harrison RW. 2021. HIV Protease: Historical Perspective and Current Research. 2021; 1–12. - PMC - PubMed
    1. Stockdale AJ, Saunders MJ, Boyd MA, Bonnett LJ, Johnston V, Wandeler G, Schoffelen AF, Ciaffi L, Stafford K, Collier AC, Paton NI, Geretti AM. Effectiveness of Protease Inhibitor/Nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the Treatment of Human Immunodeficiency Virus Type 1 infection in Sub-saharan Africa: a systematic review and Meta-analysis’, Clin. Infect Dis. 2018;66:1846–57. doi: 10.1093/cid/cix1108. - DOI - PMC - PubMed